# 04_QA_REPORT.md
# Quality Assurance Report

## Identity
| Field | Value |
|---|---|
| QA Report ID | QA-PP-0149 |
| Population Package | PP-0149 |
| Title | Hereditary Diffuse Gastric Cancer (HDGC) |
| Version | 1.0.0 |
| Status | PASS |

# 1. Content QA
| Criterion | Result |
|---|---|
| Single educational question | PASS |
| HDGC-specific scope maintained | PASS |
| CDH1 covered | PASS |
| CTNNA1 covered with appropriate hierarchy | PASS |
| Gastric-cancer risk covered | PASS |
| Lobular breast-cancer risk covered | PASS |
| Testing criteria covered | PASS |
| HDGC-like families covered | PASS |
| Positive/negative/VUS boundaries covered | PASS |
| RRTG covered | PASS |
| Endoscopic surveillance covered | PASS |
| Breast-risk management covered | PASS |
| Family/cascade implications covered | PASS |
| Misconceptions addressed | PASS |
| No unnecessary scope expansion | PASS |

# 2. Clinical QA
| Criterion | Result |
|---|---|
| Direct HDGC source used | PASS |
| NCI HDGC PDQ prioritized | PASS |
| CDH1 described as central gene | PASS |
| CTNNA1 described as less common associated gene | PASS |
| HDGC distinguished from sporadic diffuse gastric cancer | PASS |
| Risk estimates framed as population-level | PASS |
| Lobular breast-cancer risk represented | PASS |
| HDGC testing criteria represented at patient-facing level | PASS |
| HDGC-like phenotype distinguished from confirmed HDGC | PASS |
| RRTG represented as standard risk-reducing strategy | PASS |
| Endoscopic limitations represented | PASS |
| Breast surveillance represented at high level | PASS |
| Autosomal-dominant family implications represented | PASS |
| Individualized risk estimates avoided | PASS |
| Genotype–phenotype uncertainty preserved | PASS |
| VUS not equated with pathogenicity | PASS |
| Negative testing not treated as absolute reassurance | PASS |

# 3. Educational QA
| Criterion | Result |
|---|---|
| Plain-language framing | PASS |
| Medical terms explained | PASS |
| Syndrome-level framing preserved | PASS |
| Molecular biology proportional to scope | PASS |
| Patient-important decisions emphasized | PASS |
| Risks and limitations balanced | PASS |
| No deterministic language | PASS |
| No alarmist framing | PASS |
| No individual clinical advice | PASS |
| Common misconceptions included | PASS |

# 4. Governance QA
| Criterion | Result |
|---|---|
| CKO completed | PASS |
| Knowledge Passport completed | PASS |
| Evidence Package completed | PASS |
| QA Report completed | PASS |
| Gold Specification v1.0 followed | PASS |
| Approved Decision Batch implemented | PASS |
| Scope not reopened after approval | PASS |
| Evidence traceability documented | PASS |
| Knowledge Graph documented | PASS |
| Boundary/overlap declared | PASS |
| Versioning complete | PASS |

# 5. Boundary / Overlap QA

## PP-0015 — Hereditary Gastric Cancer
**Relationship:** parent/broader package. PP-0149 owns HDGC-specific syndrome, CDH1/CTNNA1, testing, risk management and family implications. **PASS**

## PP-0016 — Genetic Testing
**Relationship:** general testing framework. PP-0149 owns HDGC-specific rationale and clinical pathway. **PASS**

## Variant Interpretation
**Relationship:** detailed interpretation. PP-0149 owns patient-level pathogenic/VUS distinction only. **PASS**

## PP-0110 — Somatic Genetic Testing
**Relationship:** tumor/somatic testing. PP-0149 owns inherited germline susceptibility. **PASS**

## PP-0113 — Molecular Tumor Profiling
**Relationship:** tumor molecular profiling. PP-0149 owns hereditary syndrome. **PASS**

## PP-0114 — Genomic Biomarkers
**Relationship:** tumor genomic biomarkers. PP-0149 owns germline hereditary predisposition. **PASS**

# 6. Clinical Safety QA
| Safety Item | Result |
|---|---|
| No personal diagnosis | PASS |
| No personal cancer-risk calculation | PASS |
| No individualized surgery recommendation | PASS |
| No individualized surveillance schedule | PASS |
| No treatment recommendation | PASS |
| No implication that every carrier has cancer | PASS |
| No implication that negative testing always eliminates risk | PASS |
| No implication that VUS is pathogenic | PASS |
| No deterministic genotype–phenotype claim | PASS |
| Multidisciplinary assessment emphasized | PASS |

# 7. Evidence Traceability QA
Primary evidence: **NCI Hereditary Diffuse Gastric Cancer (PDQ®)**. Supporting evidence: NCI Genetics of Gastric Cancer (PDQ®), NCI Cancer Genetics Risk Assessment and Counseling (PDQ®), ACS Stomach Cancer, and relevant project guideline materials.

The strongest HDGC-specific claims are grounded in the NCI HDGC PDQ. Where the source materials identify uncertainty, the package preserves that uncertainty rather than filling gaps with unsupported claims.

# 8. Scope Integrity QA
**Included correctly:** HDGC, CDH1, CTNNA1, gastric risk, lobular breast risk, testing criteria, HDGC-like families, RRTG, surveillance, family implications.

**Excluded correctly:** broad hereditary gastric-cancer syndrome catalog, detailed testing methodology, detailed variant interpretation, detailed surgery/endoscopy, general breast cancer, general counseling methodology.

**Result: PASS**

# 9. Knowledge Graph QA
**Parent:** PP-0015 Hereditary Gastric Cancer

**General framework:** PP-0016 Genetic Testing

**Adjacent:** Variant Interpretation; Genetic Counseling; Gastric Cancer Screening; Lobular Breast Cancer; Risk-Reducing Surgery

**Separate molecular branch:** PP-0110 Somatic Genetic Testing; PP-0113 Molecular Tumor Profiling; PP-0114 Genomic Biomarkers in Gastric Cancer

**Result: PASS**

# 10. Gold Artifact QA
| Artifact | Present | Status |
|---|---|---|
| 01_CKO.md | Yes | PASS |
| 02_KNOWLEDGE_PASSPORT.md | Yes | PASS |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | Yes | PASS |
| 04_QA_REPORT.md | Yes | PASS |

# Final QA Decision
# PASS

PP-0149 satisfies the locked Gold Population Package requirements and is ready for repository integration.

# Final Status
**APPROVED — GOLD / QA PASS**
